ALD is an acronym for Adrenoleukodystrophy, a rare genetic condition. This disorder is not typically screened for at birth; however, there are some screening programs that may detect it in newborns.
What is Adrenoleukodystrophy (ALD)?
Adrenoleukodystrophy (ALD) is a rare genetic condition that affects the nervous system and adrenal glands. It is caused by the accumulation of very long chain fatty acids (VLCFAs) in the body, which can lead to a wide range of symptoms including learning difficulties, behavior problems, and physical disabilities.
Is ALD Screened for at Birth?
In general, ALD is not routinely screened for at birth. However, there are some screening programs that may detect it in newborns. For instance, some states in the US have implemented a newborn screening program for ALD, which tests for abnormal levels of VLCFAs in the blood. If detected, this can prompt further testing to confirm the diagnosis. In addition, some countries outside the US offer screening programs for ALD.
What are the Symptoms of ALD?
The symptoms of ALD vary depending on the type and severity of the condition. Most commonly, people with ALD experience learning difficulties, behavior problems, and physical disabilities. In severe cases, ALD can cause seizures, blindness, hearing loss, and paralysis.
How is ALD Diagnosed?
ALD is typically diagnosed through a combination of genetic testing, blood tests, and imaging studies. Genetic testing can identify the specific mutation that is causing the condition, while blood tests can measure the levels of VLCFAs in the body. Imaging studies such as MRI or CT scans can be used to assess the extent of any damage to the brain or spinal cord.